Target intelligence / Profile preview

Dihydrolipoyllysine-residue succinyltransferase component of 2-oxoglutarate dehydrogenase complex, mitochondrial (DLST)

Target
DLST
Molecular classification
Enzyme, Transferase, Acyltransferase
01

Overview

Dihydrolipoyllysine-residue succinyltransferase component of 2-oxoglutarate dehydrogenase complex, mitochondrial (DLST) is a critical enzyme that serves as the E2 subunit of the alpha-ketoglutarate dehydrogenase complex (KGDHC). Located primarily in the mitochondrial matrix, DLST catalyzes the conversion of alpha-ketoglutarate to succinyl-CoA, a key step in the tricarboxylic acid (TCA) cycle that generates NADH to fuel oxidative phosphorylation (OXPHOS). Beyond its metabolic role, a small fraction of DLST localizes to the nucleus, where it participates in histone succinylation. DLST has emerged as a promising therapeutic target in oncology, as its overexpression or amplification is associated with poor prognosis and aggressive phenotypes in neuroblastoma, triple-negative breast cancer (TNBC), and ovarian cancer. Inhibiting DLST or its complex disrupts mitochondrial energy production, leading to tumor growth arrest and apoptosis. Devimistat (CPI-613) is a lipoate analog that functionally inhibits DLST lipoylation and KGDHC activity, and is currently being evaluated in clinical trials for various malignancies.

Other names
2-oxoglutarate dehydrogenase complex component E2Dihydrolipoamide succinyltransferase component of 2-oxoglutarate dehydrogenase complexDihydrolipoamide S-succinyltransferaseOGDC-E2E2KKGD2DLTS
02

Mechanism of action

Inhibition of dihydrolipoamide S-succinyltransferase lipoylation, leading to the disruption of the alpha-ketoglutarate dehydrogenase complex (KGDHC) activity and subsequent inhibition of the mitochondrial tricarboxylic acid (TCA) cycle and oxidative phosphorylation (OXPHOS).

03

Biological functions

Tricarboxylic acid cycleLysine degradationOxidative phosphorylationHistone succinylationMetabolism
04

Disease associations

CancerCardiovascular diseaseNeurodegenerative disease
05

Safety considerations

Mitochondrial toxicitySystemic metabolic disruptionLactic acidosisNeurotoxicityCardiovascular side effects
06

Interacting drugs

1 more in the full profile.

07

Biomarkers

DLST overexpressionDLST amplificationHigh DLST mRNA levelsDLST lipoylation levels

Beyond the preview

Go deeper on Dihydrolipoyllysine-residue succinyltransferase component of 2-oxoglutarate dehydrogenase complex, mitochondrial (DLST).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dihydrolipoyllysine-residue succinyltransferase component of 2-oxoglutarate dehydrogenase complex, mitochondrial (DLST).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call